openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Adverse reactions sections page 1 of 1 · 3 matching rows.
adverse reactions
6 ADVERSE REACTIONS Serious or otherwise clinically significant adverse reactions reported in other sections of labeling: • Hypersensitivity Reactions [ see Warnings and Precautions ( 5.1 ) ] • Serotonin Syndrome [ see Warnings and Precautions ( 5.2 ) ] Most common adverse reactions in • chemotherapy-induced nausea and vomiting in adults (≥ 5%) are: headache and constipation ( 6.1 ) • postoperative nausea and vomiting (≥ 2%) are: QT prolongation, bradycardia, headache, and constipation ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Virtus at 1-888-848-3593 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Chemotherapy-Induced Nausea and Vomiting Adults In double-blind randomized clinical trials for the prevention of nausea and vomiting induced by MEC or HEC, 1374 adult patients received a single dose of Palonosetron Hydrochloride injection, ondansetron (Studies 1 and 3) or dolasetron (Study 2) administered 30 minutes prior to chemotherapy [ see Clinical Studies ( 14.1 ) ]. Adverse reactions were similar in frequency and severity in all 3 treatment groups. Common adverse reactions reported in at least 2% of patients in these trials are shown in Table 2. Table 2: Common Adverse Reactions Reported in at least 2% of patients in any treatment group in Adults with Receiving MEC (Studies 1 and 2) or HEC (Study 3) Adverse Reaction Palonosetron Hydrochloride injection 0.25 mg intravenously (N=633) Ondansetron 32 mg intravenously (N=410) Dolasetron 100 mg intravenously (N=194) Headache 9% 8% 16% Constipation 5% 2% 6% Diarrhea 1% 2% 2% Dizziness 1% 2% 2% Fatigue < 1% 1% 2% Abdominal Pain < 1% < 1% 2% Insomnia < 1% 1% 2% Less common adverse reactions, reported in 1% or less of patients, in Studies 1, 2 and 3 were: • Cardiovascular: non-sustained tachycardia, bradycardia, hypotension, hypertension, myocardial ischemia, extrasystoles, sinus tachycardia, sinus arrhythmia, supraventricular extrasystoles and QT prolongation • Dermatological: allergic dermatitis, rash • Hearing and Vision: motion sickness, tinnitus, eye irritation and amblyopia • Gastrointestinal System: diarrhea, dyspepsia, abdominal pain, dry mouth, hiccups and flatulence • General: weakness, fatigue, fever, hot flash, flu-like syndrome • Liver: transient, asymptomatic increases in AST and/or ALT and bilirubin. These changes occurred predominantly in patients receiving highly emetogenic chemotherapy. • Metabolic: hyperkalemia, electrolyte fluctuations, hyperglycemia, metabolic acidosis, glycosuria, appetite decrease, anorexia • Musculoskeletal: arthralgia • Nervous System: dizziness, somnolence, insomnia, hypersomnia, paresthesia • Psychiatric: anxiety, euphoric mood • Urinary System: urinary retention • Vascular: vein discoloration, vein distention In other studies, 2 subjects experienced severe constipation following a single Palonosetron Hydrochloride injection dose of approximately 0.75 mg (three times the recommended dose). Pediatrics Aged 2 Months to 17 Years In a pediatric clinical trial, 163 pediatric cancer patients with a mean age of 8 years received a single 20 mcg/kg (maximum 1.5 mg) intravenous infusion of Palonosetron Hydrochloride injection 30 minutes before beginning the first cycle of emetogenic chemotherapy [ see Clinical Studies ( 14.2 ) ]. Adverse reactions were evaluated in pediatric patients receiving Palonosetron Hydrochloride injection for up to 4 chemotherapy cycles. The following adverse reactions were reported in less than 1% of patients: • Nervous System: headache, dizziness, dyskinesia • General: infusion site pain • Dermatological: allergic dermatitis, skin disorder Postoperative Nausea and Vomiting The most common adverse reactions reported in at least 2% of adults receiving Palonosetron Hydrochloride injection 0.075 mg intravenously immediately before induction of anesthesia in 3 randomized placebo-controlled trials [ see Clinical Studies ( 14.3 ) ] are shown in Table 3. Rates of adverse reactions between Palonosetron Hydrochloride injection and placebo groups were similar. Some events are known to be associated with, or may be exacerbated by, concomitant perioperative and intraoperative medications administered in this surgical population. A thorough QT/QTc study demonstrated Palonosetron Hydrochloride injection does not prolong the QT interval to any clinically relevant extent [ see Clinical Pharmacology ( 12.2 ) ]. Table 3: Common Adverse Reactions Reported in at least 2% of patients in any treatment group in Trials of Adults with Postoperative Nausea and Vomiting Adverse Reaction Palonosetron Hydrochloride injection 0.075 mg intravenously (N=336) Placebo (N=369) Electrocardiogram QT prolongation 5% 3% Bradycardia 4% 4% Headache 3% 4% Constipation 2% 3% Less common adverse reactions, reported in 1% of less of patients, in these PONV clinical trials were: • Cardiovascular: QTc prolongation, sinus bradycardia, tachycardia, blood pressure decreased, hypotension, hypertension, arrhythmia, ventricular extrasystoles, generalized edema, ECG T wave amplitude decreased, platelet count decreased. The frequency of these adverse effects did not appear to be different from placebo. • Dermatological: pruritus • Gastrointestinal System: flatulence, dry mouth, upper abdominal pain, salivary hypersecretion, dyspepsia, diarrhea, intestinal hypomotility, anorexia • General: chills • Liver: increases in AST and/or ALT, hepatic enzyme increased • Metabolic: hypokalemia, anorexia • Nervous System: dizziness • Respiratory: hypoventilation, laryngospasm • Urinary System: urinary retention 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of palonosetron hydrochloride. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. • Hypersensitivity reactions: including dyspnea, bronchospasm, swelling/edema, erythema, pruritus, rash, urticaria, anaphylaxis and anaphylactic shock [ see Warnings and Precautions ( 5.1 ) ] • Injection site reactions: including burning, induration, discomfort and pain